Zhejiang Starry PharmaceuticalLtd Gestione

Gestione criteri di controllo 2/4

Zhejiang Starry PharmaceuticalLtd Il CEO è Weiyi Shen, nominato in May2023, ha un mandato di 1.5 anni. possiede direttamente 0.003% delle azioni della società, per un valore di CN¥ 129.35K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.5 anni e 1.5 anni.

Informazioni chiave

Weiyi Shen

Amministratore delegato

CN¥556.0k

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	1.5yrs
Proprietà del CEO	0.003%
Durata media del management	1.5yrs
Durata media del Consiglio di amministrazione	1.5yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Weiyi Shen (44 yo)

1.5yrs

Mandato

CN¥556,000

Compensazione

Mr. Weiyi Shen is Vice Chairman of Zhejiang Starry Pharmaceutical Co.,Ltd. since November 01, 2021 and serves as its General Manager since May 18, 2023. He joined the Zhejiang Starry Pharmaceutical Co.,Ltd...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Weiyi Shen	Vice Chairman & GM	1.5yrs	CN¥556.00k	0.0027% CN¥ 129.3k
Junfeng Guo	Financial Director	1.9yrs	CN¥269.40k	0.00059% CN¥ 28.6k
Chao Sun	Board Secretary	2.3yrs	CN¥316.40k	0.0010% CN¥ 50.9k
Chaoyang Yao	Deputy General Manager	1.3yrs	CN¥256.50k	0.0064% CN¥ 308.1k
Chun Ye	Deputy General Manager	1.3yrs	CN¥544.80k	Nessun dato
Haiyasheng Li	Accounting Supervisor	no data	Nessun dato	Nessun dato

1.5yrs

Durata media

44yo

Età media

Gestione esperta: Il team dirigenziale di 603520 non è considerato esperto (durata media 1.5 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Weiyi Shen	Vice Chairman & GM	3yrs	CN¥556.00k	0.0027% CN¥ 129.3k
Jin Sheng Hu	Director	no data	CN¥1.26m	10.28% CN¥ 498.0m
Jian Hu	Chairman	1.5yrs	CN¥683.50k	10.56% CN¥ 511.7m
Meiying Mao	Independent Director	1.5yrs	CN¥60.00k	Nessun dato
Lingqiao Li	Supervisor	4.6yrs	Nessun dato	Nessun dato
Fangwei Zheng	Chairman of the Supervisory Board	1.5yrs	Nessun dato	0.0077% CN¥ 371.1k
Hongfei Zhang	Supervisor	1.5yrs	Nessun dato	0.0022% CN¥ 105.6k
Xiao Ke Zhang	Independent Director	1.5yrs	CN¥60.00k	Nessun dato
Xu Gang	Director	1.5yrs	Nessun dato	Nessun dato
Jiming Hu	Independent Director	1.5yrs	CN¥60.00k	Nessun dato

1.5yrs

Durata media

46yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di 603520 non è considerato esperto (durata media del mandato 1.5 anni), il che suggerisce un nuovo consiglio.

Zhejiang Starry PharmaceuticalLtd Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Zhejiang Starry Pharmaceutical Co.,Ltd., Annual General Meeting, May 21, 2024

Less than half of directors are independent

Recent updates

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Aug 23, 2024

New minor risk - Shareholder dilution

Zhejiang Starry Pharmaceutical Co.,Ltd., Annual General Meeting, May 21, 2024

Full year 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.22 loss in FY 2022)

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Apr 19, 2024

Third quarter 2023 earnings released: EPS: CN¥0.011 (vs CN¥0.15 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.066 (vs CN¥0.048 loss in 2Q 2022)

Zhejiang Starry Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Full year 2022 earnings released: CN¥0.22 loss per share (vs CN¥0.94 profit in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.15 loss per share (vs CN¥0.19 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.048 loss per share (vs CN¥0.27 profit in 2Q 2021)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2021 earnings released: EPS: CN¥1.32 (vs CN¥1.00 in FY 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.25 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.38 (vs CN¥0.40 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.26 (vs CN¥0.19 in 1Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

New 90-day low: CN¥58.80

New 90-day low: CN¥59.50

Market bids up stock over the past week

New 90-day low: CN¥66.75

Third quarter earnings released

Zhejiang Starry Pharmaceutical Co., Ltd. to Report Q3, 2020 Results on Oct 30, 2020

New 90-day low: CN¥68.34

First half earnings released

Zhejiang Starry Pharmaceutical Co., Ltd. announced that it has received CNY 671.999962 million in funding from a group of investors

Zhejiang Starry Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media